Topotecan in the First-Line Treatment of Small Cell Lung Cancer

Topotecan in the First-Line Treatment of Small Cell Lung Cancer David J. Stewart Oncologist 2004; 9: 33-42 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in lung cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Discuss the role of topotecan combinations as first-line therapy for SCLC. Discuss the role of single-agent topotecan as first-line therapy or consolidation therapy for SCLC. Discuss the toxicity profile of topotecan alone and in combinations. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Dec. 22, 2004 Most Recent Review: Dec. 22, 2004* Most Recent Update: Dec. 22, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.